REGENXBIO Inc. reported its financial results for the second quarter ended June 30, 2025, on August 7, 2025. Cash, cash equivalents, and marketable securities increased to $363.6 million as of June 30, 2025.
This increase was primarily due to the $110.0 million upfront payment from the Nippon Shinyaku partnership in March 2025 and $144.5 million in net proceeds from the royalty monetization with HCRx in May 2025. Total revenues for Q2 2025 were $21.4 million, a decrease from $22.3 million in Q2 2024, mainly due to lower Zolgensma royalties.
The net loss for Q2 2025 was $70.9 million, or $1.38 per share, compared to a net loss of $53.0 million, or $1.05 per share, in Q2 2024. The company expects its cash position to fund operations into early 2027, excluding potential monetization of a Priority Review Voucher.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.